Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002115 | A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease. | PHASE1 | COMPLETED | 20 | — | — | - | - | Jun 24, 2005 | 1 | United States |
| NCT00002326 | The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients | PHASE1 | COMPLETED | 20 | — | — | - | - | Jun 24, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Adefovir | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Other antiretroviral therapy IF on a stable dose for at least 4 weeks prior to study entry. * Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole IF...